STK11

Tumour Suppressor
Serine/threonine-protein kinase STK11 UniProt accession Q15831

Tumor suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage response. Acts by phosphorylating the T-loop of AMPK family proteins, thus promoting their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not MELK. Also phosphorylates non-AMPK family proteins such as STRADA, PTEN and possibly p53/TP53.

Acts as a key upstream regulator of AMPK by mediating phosphorylation and activation of AMPK catalytic subunits PRKAA1 and PRKAA2 and thereby regulates processes including: inhibition of signaling pathways that promote cell growth and proliferation when energy levels are low, glucose homeostasis in liver, activation of autophagy when cells undergo nutrient deprivation, and B-cell differentiation in the germinal center in response to DNA damage. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton. Required for cortical neuron polarization by mediating phosphorylation and activation of BRSK1 and BRSK2, leading to axon initiation and specification.

Involved in DNA damage response: interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to participate in transcription activation. Able to phosphorylate p53/TP53; the relevance of such result in vivo is however unclear and phosphorylation may be indirect and mediated by downstream STK11/LKB1 kinase NUAK1. Also acts as a mediator of p53/TP53-dependent apoptosis via interaction with p53/TP53: translocates to the mitochondrion during apoptosis and regulates p53/TP53-dependent apoptosis pathways.

Regulates UV radiation-induced DNA damage response mediated by CDKN1A. In association with NUAK1, phosphorylates CDKN1A in response to UV radiation and contributes to its degradation which is necessary for optimal DNA repair (PubMed:25329316)

Source: UniProt

Catalytic component of a trimeric complex composed of STK11/LKB1, STRAD (STRADA or STRADB) and CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta): the complex tethers STK11/LKB1 in the cytoplasm and stimulates its catalytic activity. Found in a ternary complex composed of SMAD4, STK11/LKB1 and STK11IP. Interacts with p53/TP53, SMAD4, STK11IP and WDR6.

Interacts with NR4A1. Interacts with NISCH; this interaction may increase STK11 activity. Interacts with PTEN; leading to PTEN phosphorylation.

Interacts with SIRT1; the interaction deacetylates STK11. Interacts with CDKN1A

Source: UniProt
Nucleus, Cytoplasm, Membrane, Mitochondrion Nucleus, Cytoplasm
Source: UniProt

Ubiquitously expressed. Strongest expression in testis and fetal liver

Source: UniProt
  • Peutz-Jeghers syndrome (PJS)

    An autosomal dominant disorder characterized by melanocytic macules of the lips, multiple gastrointestinal hamartomatous polyps and an increased risk for various neoplasms, including gastrointestinal cancer.

  • Testicular germ cell tumor (TGCT)

    A common malignancy in males representing 95% of all testicular neoplasms. TGCTs have various pathologic subtypes including: unclassified intratubular germ cell neoplasia, seminoma (including cases with syncytiotrophoblastic cells), spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.

  • Unknown disease
Source: UniProt
  • AMPK inhibits chREBP transcriptional activation activity
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • Regulation of TP53 Activity through Phosphorylation
  • FOXO-mediated transcription of cell death genes
Source: Reactome via UniProt

Mutations

Cancer Type Mutation Percentage
Central Nervous System Astrocytoma Grade Iv 0.28%
Lung Adenocarcinoma 10.82%
Lung Small Cell Carcinoma 0.30%
Lung Squamous Cell Carcinoma 0.54%
Oesophagus Adenocarcinoma 1.24%
Oesophagus Squamous Cell Carcinoma 0.12%
Pancreas Ductal Carcinoma 0.73%

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to STK11, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 477

NCT ID Condition Brief Title Phase Status
NCT05180799 NSCLC, Melanoma A Phase 1/2 Study of BA3071 in Patients With Solid Tumors PHASE1, PHASE2 ACTIVE_NOT_RECRUITING
NCT04257045 Breast Carcinoma, Deleterious CDH1 Gene Mutation, Deleterious DICER1 Gene Mutation, Deleterious SMARCA4 Gene Mutation, Deleterious STK11 Gene Mutation, Endometrial Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives N/A COMPLETED
NCT03785249 Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 PHASE1, PHASE2 ACTIVE_NOT_RECRUITING
NCT06128551 Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors PHASE1, PHASE2 RECRUITING
NCT07207395 Lung Cancer (NSCLC) A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation. PHASE2 RECRUITING
NCT05887492 Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors PHASE1, PHASE2 RECRUITING
NCT06124963 Gastric Type Adenocarcinoma (GAS) With STK11 Mutation A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations PHASE2 RECRUITING
NCT06219174 Non Small Cell Lung Cancer, Lung Cancer Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) PHASE1, PHASE2 SUSPENDED
NCT05054725 Non-Small Cell Lung Cancer Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies PHASE2 COMPLETED
NCT06008093 Carcinoma, Non-Small-Cell Lung A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS PHASE2 ACTIVE_NOT_RECRUITING